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Acetylcholine mediates cell-to-cell communications in
the skin. Human epidermal keratinocytes respond to
acetylcholine via two classes of cell-surface receptors, the
nicotinic and the muscarinic cholinergic receptors. High
affinity muscarinic acetylcholine receptors (mAChR)
have been found on keratinocyte cell surfaces at high
density. These receptors mediate effects of muscarinic
drugs on keratinocyte viability, proliferation, adhesion,
lateral migration, and differentiation. In this study, we
investigated the molecular structure of keratinocyte
mAChR and their location in human epidermis. Poly-
merase chain reaction amplification of cDNA sequences
uniquely present within the third cytoplasmic loop of
each subtype demonstrated the expression of the m1,
m3, m4, and m5 mAChR subtypes. To visualize these
mAChR, we raised rabbit anti-sera to synthetic peptide
analogs of the carboxyl terminal regions of each subtype.
The antibodies selectively bound to keratinocyte mAChR
subtypes in immunoblotting membranes and epidermis,
both of which could be abolished by preincubating the
Human epidermal keratinocytes are members of a non-neuroneal signaling network mediating intercellularcommunication in the skin in which the cytotransmit-ter acetylcholine (ACh) acts as a local hormone, or acytokine (Grando and Horton, 1997). Non-neuroneal
ACh is synthesized, secreted, and degraded by keratinocytes, and exerts
a plethora of biologic effects on these cells because it can simultaneously
activate different intracellular signal transduction cascades (reviewed by
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anti-serum with the peptide used for immunization. The
immunofluorescent staining patterns produced by each
antibody in the epidermis suggested that the profile of
keratinocyte mAChR changes during epidermal turnover.
The semiquantitative analysis of fluorescence revealed
that basal cells predominantly expressed m3, prickle cells
had equally high levels of m4 and m5, and granular cells
mostly possessed m1. Thus, the results of this study
demonstrate for the first time the presence of m1, m3,
m4, and m5 mAChR in epidermal keratinocytes. Because
keratinocytes express a unique combination of mAChR
subtypes at each stage of their development in the epi-
dermis, each receptor may regulate a specific cell func-
tion. Hence, a single cytotransmitter, acetylcholine, and
muscarinic drugs may exert different biologic effects on
keratinocytes at different stages of their maturation.
Key words: antipeptide antibody production/immunoblotting/
polymerase chain reaction amplification of intronless gene
sequences/semiquantitative immunofluorescence. J Invest
Dermatol 111:410–416, 1998
Grando, 1997). ACh binds to keratinocytes via two distinct classes of
cholinergic cell-surface receptors: (i) the ACh-gated ion channels
comprised of different nicotinic receptor subunits; and (ii) the G
protein-coupled single-subunit transmembrane glycoproteins – the
muscarinic acetylcholine receptors (mAChR) (Grando et al, 1995a, b).
Whereas the nicotinic receptors mediate the transmembrane flow of
Na1, K1, and Ca11, the mAChR convert ACh signals into metabolic
responses through the interactions of G proteins with signal transducing
enzymes, leading to increases or decreases in second messengers, ion
concentrations, and modulations of protein kinase activities. Muscarinic
drugs have been shown to exhibit dramatic effects on keratinocyte
proliferation, migration, cell-to-substrate and cell-to-cell adhesion, and
differentiation. These effects may involve mAChR-dependent changes
in transmembrane Ca11 flux and intracellular metabolism (Grando
and Dahl, 1993; Grando et al, 1993a; Grando and Horton, 1997).
The heterogeneity of mAChR had been suggested by their variable
affinity for various pharmacologic ligands, and then demonstrated by
molecular cloning the genes coding for these receptors (Bonner, 1989;
Mei et al, 1989). It has been determined that the family of mAChR is
comprised of at least four pharmacologic (M1–M4) and five molecular
(m1–m5) subtypes. The pharmacologic analysis demonstrated that
human keratinocytes express µ2.5 3 105 high affinity mAChR per
cell (Grando and Dahl, 1993; Grando et al, 1995b), and preliminary
data indicated that not all of these mAChR are identical (Grando and
Horton, 1997). Whereas experiments designed to elucidate the cellular
functions regulated by each pharmacologic subtype of keratinocyte
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mAChR are being conducted using subtype-specific muscarinic drugs,1
the localization of molecular subtypes expressed by keratinocytes and
other skin cells has been awaiting development of subtype-specific
antibodies.
In this study, we established the molecular subtypes of mAChR
expressed by human keratinocytes, developed subtype-specific anti-
bodies, and mapped keratinocytes expressing each mAChR subtype to
a specific epidermal layer. We found that at each stage of their
maturation in epidermis, keratinocytes express different combinations
of mAChR subtypes, which could allow a single cytotransmitter ACh
to control selectively keratinocyte functions at different stages of cell
development.
MATERIALS AND METHODS
Cell and tissue source Normal human skin samples were obtained from
circumcision of neonatal foreskins and other surgical procedures (this study has
been approved by the University of California Davis Human Subjects Review
Committee). The skin specimens destined for immunohistochemistry were snap
frozen in liquid nitrogen and stored at –80°C until use. Those skin samples
destined for keratinocyte cultures were freed of fat tissue and clotted blood,
rinsed in Ca11- and Mg11-free phosphate-buffered saline (Gibco BRL,
Gaithersburg, MD), and cut into 3–4 mm pieces. The pieces of skin were
placed epidermis up into 35 mm Petri dishes (Falcon 3001, Becton Dickinson
Labware, Lincoln Park, NJ) containing 2.5 ml of 0.125% trypsin (Sigma, St.
Louis, MO) and 2.5 ml of minimum essential medium (Gibco BRL) supple-
mented to contain 50 µg gentamicin sulfate per ml, 50 µg kanamycin sulfate
per ml, 10 U penicillin G per ml, 10 µg streptomycin per ml, and 5 µg
amphotericin B per ml (all from Gibco BRL), and incubated overnight at 37°C
in a humidified atmosphere with 5% CO2. The following day the epidermis
was separated from the dermis and individual keratinocytes were released by
rapid pipetting or vortexing for about 15 s in minimum essential medium
supplemented to contain 20% heat inactivated newborn calf serum (Gibco
BRL). The resultant keratinocyte suspension was inoculated into 25 cm2 culture
flasks (Corning Glass Works, Corning, NY) and cultured in serum-free
keratinocyte growth medium containing 0.09 mM Ca11 (Gibco BRL). After
cultures reached µ70%–80% confluence, the cells were further subcultured
into 75 cm2 flasks. In some cultures, keratinocyte differentiation was stimulated
by increasing the concentration of Ca11 in keratinocyte growth medium to
1.8 mM during the last 24–72 h of incubation.
Polymerase chain reaction (PCR) amplification of intronless
sequences Cultured keratinocytes were scraped from the bottom of the flasks
with a rubber policemen, and total RNA samples were prepared using the
guanidium thiocyanate-phenol-chloroform extraction procedure (Chomczynski
and Sacchi, 1987). To remove contaminating genomic DNA, total RNA was
incubated for 30 min at 37°C in a solution containing 2.5 U RNase-free
DNase I (Gibco BRL) in 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2 mM
MgCl2, and 40 U of RNase Block (Stratagene, La Jolla, CA). This reaction
was stopped by adding 4 mM ethylenediamine tetraacetic acid and DNase I
inactivated by heating the samples for 10 min at 65°C. The DNase-treated
RNA samples (5 µg) underwent reverse transcription (RT) in 50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 5 mM dithiothreitol, 60 U RNase
Block, 10 µM random decamer primers (dN)10, 600 U RNase H-free reverse
transcriptase (Superscript; Gibco BRL), and 0.5 mM each of dATP, dCTP,
dGTP, and dTTP in a final volume of 60 µl. The synthesis of single-stranded
cDNA was carried out for 80 min at 42°C. To amplify different members of
the human mAChR gene family, we designed primers to match specific
sequences of each mAChR molecular subtype (Peralta et al, 1987; Bonner et al,
1988; Bonner, 1989). The sense and anti-sense primers were: for m1, 59-
AGACGCCAGGCAAAGGGGGTGG-39 and 59-CACGGGGCTTCTGGC-
CCTTGCC-39 (expected size 348 bp); for m2, 59-ACAAGAAGGAGC-
CTGTTGCCAACC-39 and 59-CAATCTTGCGGGCTACAATATTCTG-39
(438 bp); for m3, 59-GACAGAAAACTTTGTCCACCCCAC-39 and 59-
AGAAGTCTTAGCTGTGTCCACGGC-39 (496 bp); for m4, 59-TCCTCA-
AGAGCCCACTAATGAAGC-39 and 59-TTCTTGCGCACCTGGTTGCG-
AGC-39 (430 bp); and for m5, 59-CTCACCACCTGTAGCAGCTACCC-39
and 59-CTCTCTTTCGTTTGGTCATTTGATG-39 (397 bp). The PCR were
performed in a final volume of 50 µl containing 8 µl of the RT product,
10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 1 mM MgCl2,
0.2 mM each of dATP, dCTP, dGTP, dTTP, 2.5 U Taq DNA polymerase
1Zia S, Buchli R, Ndoye A, Greenberg B, Nguyen V-T, Grando SA: The
m4 keratinocyte muscarinic receptor regulates cell motility and modulates
intracellular calcium. J Invest Dermatol 110:545, 1998 (abstr.)
(Promega, Madison, WI), and 1 µM each of the sense and corresponding anti-
sense primer pairs. The reaction mixture was first heated at 94°C (5 min) before
DNA polymerase was added. Cycling was performed at 95°C (60 s), 60°C
(60 s), and 72°C (120 s) for 35 cycles. After a period of 20 cycles, the time for
the elongation step at 72°C was increased (15 s) for every new cycle. The final
cycle had an additional extension time of 10 min at 72°C. The PCR products
were electrophoresed on 1.5% agarose gels containing 1 µg ethidium bromide
per ml and photographed under fluorescent UV illumination. The size of each
PCR product was estimated by using a 250 bp DNA ladder standard (Gibco
BRL). To verify that the PCR products indeed represented authentic sequences
of human mAChR, the appropriately sized DNA bands were subjected to
restriction analysis (see Results), and sequenced.
The PCR amplification of intronless sequences necessitated inclusion of
additional controls. To control the adequacy of PCR primers, non-DNase-
treated samples containing genomic DNA were used as the template. To control
for contamination of DNase-treated samples with residual genomic DNA, the
RT step was omitted. Lastly, to control for template contamination at every
step, an empty tube was subjected to the same procedure as all other samples.
Generation of the mAChR subtype-specific antibodies The m1, m3,
m4, and m5 receptor subtype specific anti-sera were generated using synthetic
peptide analogs of the carboxyl termini of these proteins by procedures
previously described by us (Lark et al, 1995). The following peptides were used
for immunization: for m1, Ac-SVHRTPSRCQ (residue numbers 451–460);
for m3, CFHKRVPEQAL (579–589); for m4, CQYRNIGTAR (469–478);
and for m5, CEEKLYWQGNSKLP (518–531). The peptides were conjugated
onto bovine thyroglobulin specifically through the Cys residue that was
incorporated into each structure, and the conjugates purified before being used
to immunize groups of rabbits. The anti-serum collected from each bleed of
each animal was tested by enzyme-linked immunosorbent assay (ELISA) for
the presence of antibodies specific for the immunogen peptide. Only anti-sera
that recognized a specific receptor subtype by ELISA were selected for
experiments with keratinocytes.
Immunoblotting The localization of keratinocyte mAChR in western blots
employed cellular proteins obtained by lysing directly monolayers of 70%–80%
confluent second passage human neonatal foreskin keratinocyte cultures with a
solution containing 4% sodium dodecyl sulfate, 20% glycerol, 0.02% bromo-
phenol blue, and 200 mM dithiothreitol in 0.5 M Tris-HCl (pH 6.8). Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western
blot analysis were performed by a modification of the procedure previously
described by us (Webber et al, 1994). Briefly, the proteins were separated on
10% gels, electroblotted onto the Immobilon-P membranes (Millipore, Bedford,
MA), and blocked overnight with 4% normal goat serum and 20% evaporated
goat milk in Tris-buffered saline/Tween 20 buffer, and all primary and secondary
antibodies were applied in the same buffer. For blocked antibody controls,
150 nM of the peptide immunogen was added to 6.0 ml of the diluted rabbit
polyclonal antibody solution, and preincubated for at least 45 min at 37°C
before applying to the membrane. The blots were developed using the enhanced
diaminobenzidine reaction.
Semi-quantitative immunofluorescence assays The indirect immuno-
fluorescence experiments were performed as detailed elsewhere (Grando et al,
1995b), with minor modifications. Briefly, 4–8 µm sections of freshly frozen
normal human skin were fixed for 3 min with phosphate-buffered saline
(pH 7.35) containing 3% formaldehyde freshly prepared from paraformaldehyde
and 7% sucrose, and incubated overnight at 4°C with a primary anti-mAChR
subtype-specific antibody diluted 1:1000. After washing, the specimens were
exposed for 1 h at room temperature to the secondary, fluorescein-isothiocyanate
conjugated swine anti-rabbit IgG antibody (DAKO, Carpenteria, CA) diluted
1:30 in phosphate-buffered saline. The indirect immunofluorescence images
were acquired using a computer-linked, video-monitored Axiovert 135 fluores-
cence microscope (Carl Zeiss, Thornwood, NY), equipped with a CCD video
camera (PTI, Monmouth Junction, NJ), and analyzed with image analysis
software (Signal Analytics, Vienna, VA). The relative amounts of each mAChR
subtype were estimated by the previously described semiquantitative immuno-
fluorescence assay (Zia et al, 1997), which is based on calculating the intensity
of fluorescence pixel by pixel by dividing the summation of pixels of fluorescence
intensity by the segment occupied by the pixels (i.e., a square template of fixed
size that covers an area of epidermis that is equivalent to an average sized
keratinocyte), and then subtracting the mean intensity of fluorescence of the
background (i.e., a tissue-free segment of the same size). For each skin specimen,
at least three different randomly selected segments in at least three different
microscopic fields were analyzed.
Statistics The results of the quantitative assays were expressed as mean 6
SD. Significance was determined using Student’s t test.
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Figure 1. PCR amplification of mAChR
sequences from human epidermal ker-
atinocyte RNA. Agarose gel electrophoresis
of PCR products amplified from DNase-treated
keratinocyte RNA samples reverse-transcribed
to cDNA (lanes 1–5, ‘‘experiment’’), DNase
nontreated keratinocyte RNA samples con-
taining residual genomic DNA (lanes 7–11,
‘‘positive control’’), DNase-treated keratinocyte
RNA samples in which the RT step was omitted
to check for residual genomic DNA (lanes 13–
17, ‘‘negative control’’), and an empty tube
that was subjected to the same procedures as
experimental sample to control for template
contamination at every step (lanes 19–23, ‘‘nega-
tive control’’). Five micrograms of purified total
RNA extracted from keratinocytes cultured at
1.8 mM Ca11 were reverse-transcribed to
cDNA and amplified for 35 cycles with five
pairs of mAChR subtype-specific primers. The
size of each amplification product was deter-
mined using the 250 bp DNA ladder standard
loaded in lanes 6, 12, and 18. These results were
reproduced in three independent experiments.
The bands amplified from the experimental
samples were subjected to the restriction
enzyme analysis, and directly sequenced. Both
procedures verified that the products amplified
from keratinocyte cDNA contained authentic
sequences of human m1, m3, m4, and m5
mAChR subtypes.
RESULTS
Human epidermal keratinocytes contain mRNA of m1, m3,
m4, and m5 mAChR subtypes The expression of the genes coding
for various molecular subtypes of mAChR in human keratinocytes
was analyzed using RNA isolated from keratinocyte cultures. As seen
in Fig 1, each PCR experiment included one positive and two negative
controls. The positive control checked for the adequacy of PCR
primer pairs, whereas the negative control verified that PCR products
were amplified from reverse transcribed mRNA and not from con-
taminating genomic DNA.
When cDNA from keratinocyte mRNA was used in PCR experi-
ments, the sequences corresponding to authentic m1, m3, m4, and
m5, but not to m2, were amplified. These PCR yielded products with
the expected size. To confirm their identity, the aliquots of PCR
products were examined by restriction analysis, using Nco I (for m1),
Hind III (m3), Sac II (m4), and Eco RI (m5). The actual sizes of the
obtained fragments were as predicted from the DNA sequence (data
not shown). The PCR products were also re-amplified and directly
sequenced, further demonstrating their identity with human mAChR.
The m3 mRNA was detected after keratinocyte monolayers were
fed with keratinocyte growth medium containing 1.8 mM Ca11 for
72 h. In keratinocytes cultured in keratinocyte growth medium
containing 0.09 mM Ca11, the m3 was undetectable in two independ-
ent experiments.
In positive control experiments, using non-DNAse treated samples
of keratinocyte nucleic acids, PCR primers amplified sequences of all
five mAChR subtypes (Fig 1). In these experiments, the m2 sequence
was amplified from genomic DNA. Because the mAChR genes do
not contain introns (Peralta et al, 1987; Bonner et al, 1988; Bonner,
1989), each amplification product derived from genomic DNA was of
the same size as the corresponding amplification product derived from
the cDNA.
The negative control experiments were performed to verify that
our approach to distinguishing between genomic DNA and mRNA
was adequate. In these experiments, the RNA samples were treated
with DNase (as were the experimental RNA samples), but the RT
step was omitted. As expected, no amplified product was generated
either in these samples or in the other negative control samples that
lacked the RNA templates (Fig 1).
Characterization of antibodies to keratinocyte mAChR
subtypes The anti-serum to each keratinocyte mAChR subtype,
m1, m3, m4, and m5, was characterized for its ability to recognize
and bind to the specific amino acid sequence used to elicit its
production. Each anti-serum was tested by ELISA titration for its
ability to bind to the peptide analog, used as immunogen adsorbed
directly onto the microtiter plate (data not shown). Antibody specificity
in ELISA was determined by the lack of recognition of unrelated
amino acid sequences. No cross-reaction with the other mAChR
subtype specific peptides or unrelated receptor peptides was found
with any of the anti-sera used in these experiments (data not shown).
Subtype-specific mAChR antibodies label keratinocyte mAChR
proteins in western blots The antibodies specific to m1, m3, m4,
and m5 mAChR subtypes were used to probe keratinocyte mAChR
subtypes among keratinocyte proteins resolved by SDS-PAGE. As seen
in Fig 2, all four receptors subtypes could be visualized. The m1
subtype migrated with molecular mass (Mr) of µ60 kDa. Both m3 and
m4 proteins appeared at the 65 kDa region, whereas the m5 subtype
was visualized at µ95 kDa (Fig 2).
The specificity of antibody binding to keratinocyte mAChR in
western blots was determined by the ability of only the corresponding
immunogen peptide to block the binding of the antibody to the
membrane bound protein (data not shown). No protein bands were
seen if the primary antibody was omitted (data not shown).
Localization of keratinocyte mAChR subtypes in human
epidermis Antibodies to each of the four mAChR subtypes found
to be expressed by keratinocytes, namely, m1, m3, m4, and m5,
produced an intercellular staining pattern in normal human epidermis
consistent with the presence of receptor molecules on keratinocyte cell
membranes, as has been previously demonstrated by immunoelectron
microscopy (Grando et al, 1995b). The m1 antibody selectively stained
cell membranes of keratinocytes comprising the granular cell layer
(Fig 3a). The staining for m3 was localized to the basal cell layer
VOL. 111, NO. 3 SEPTEMBER 1998 KERATINOCYTE MUSCARINIC RECEPTOR SUBTYPES 413
(Fig 3b). In addition to the areas of cell-to-cell contact, the m3
antibody also specifically stained areas of the cell membrane covering
wide cytoplasmic aprons of basal cells. The bulk of m4 immunoreactivity
was seen in the prickle cell layer (Fig 3c). The intensity of staining
produced by the m4 antibody gradually increased from the innermost
to the uppermost rows of prickle cells. The distinct intercellular,
fishnet-like staining pattern produced by m5 antibody was distributed
evenly throughout the epidermal layers (Fig 3d).
The indirect immunofluorescence staining was abolished by pre-
Figure 2. Visualization of mAChR subtypes in western blots of ker-
atinocyte proteins. Results of a representative experiment showing protein
bands recognized by rabbit polyclonal antibodies specific for m1, m3, m4, and
m5 mAChR subtypes among keratinocyte proteins resolved by SDS-PAGE
and immunoblotted as detailed in Materials and Methods. Before SDS-PAGE,
keratinocyte monolayers were cultured for 24 h in keratinocyte growth medium
containing 1.8 mM Ca11. The working dilution of primary antibody was
1:250 and that of secondary, goat anti-rabbit IgG antibody was 1:2500. The
bands did not appear in the control experiments, in which immunoblotted
membranes were treated without primary antibody or in which the anti-peptide
anti-sera were preincubated with the m1, m3, m4, and m5 specific peptides used
for immunization. The apparent Mr of each receptor protein is shown in kDa.
Figure 3. Immunolocalization of mAChR
subtypes in human epidermis. The cryostat
sections of freshly frozen normal human skin
specimens were fixed and treated overnight
with rabbit anti-sera raised against synthetic
peptides representing the carboxyl terminus of
(a) m1, (b) m3, (c) m4, and (d) m5. Binding of
the primary antibodies was visualized using
secondary, fluorescein-isothiocyanate-labeled
anti-rabbit IgG antibody (see Materials and
Methods). Both preincubation of the anti-pep-
tide immune sera with the synthetic peptides
used for immunization and omitting the primary
antibody abolished the fluorescent staining.
incubating the specific anti-serum with the synthetic peptide used to
elicit the antibody (data not shown).
Semi-quantitative analysis of mAChR subtypes expressed by
keratinocytes at different stages of cell differentiation The
relative amounts of each molecular subtype of mAChR expressed at
various stages of keratinocyte development in epidermis were estimated
by using computer-assisted analysis of the intensity of fluorescence
(Fig 4a). The relative amount of m1 in granular cells was found to be
significantly higher (p , 0.05) than in less mature keratinocytes. The
basal cells expressed two and three times more m3 as compared with
Figure 4. Relative amounts of mAChR subtypes expressed at different
stages of keratinocyte development in epidermis. The indirect immuno-
fluorescence images of normal human epidermis stained with m1, m3, m4, and
m5 antibodies were acquired using a computer-linked Axiovert 135 fluorescence
microscope through a CCD video camera and analyzed by image analysis
software as detailed in Materials and Methods. The data are mean 6 SD of
relative amounts of mAChR subtypes computed in three different segments of
three different microscopic fields on at least three skin specimens (m1 antibody,
n 5 3; m3 antibody, n 5 4; m4 antibody, n 5 4; and m5 antibody, n 5 3).
(a) The relative amounts of each mAChR subtype expressed by basal, prickle,
and granular cells; (b) the same data reorganized to better observe the
profile of mAChR subtypes expressed at each particular stage of keratinocyte
development in epidermis.
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granular and prickle cells, respectively. The relative amount of m4
expressed by prickle cells was significantly greater (p , 0.05) than that
expressed by basal and granular cells. The relative amounts of m5
expressed by keratinocytes at different stages of their differentiation
were rather similar.
Figure 4(b) illustrates the profile of mAChR subtypes at each stage
of keratinocyte development in epidermis. It appears that basal cells
predominantly express m3 and to a lesser extent m5. Only negligible
amounts of m1 and m4 are present in basal cells. The prickle cells
chiefly express m4 and m5 and significantly less m1 and m3 (p , 0.05).
The predominant mAChR subtype expressed by granular cells is m1.
Granular cells also express other mAChR subtypes in the following
relative amounts: m5 . m4 . m3, all of which are significantly less
as compared with the relative amount of m1 (p , 0.05).
DISCUSSION
In this study, we demonstrated for the first time that normal human
epidermal keratinocytes both in vivo and in vitro express the m1, m3,
m4, and m5 molecular subtypes of mAChR, and that the time and
the level of the expression of each subtype depend upon the stage of
keratinocyte differentiation.
Five mAChR genes (m1–m5) that encode distinct mAChR subtypes
have been cloned (Bonner et al, 1987, 1988; Peralta et al, 1987).
Because of their structural homology and pharmacologic similarity,
ligand binding probes currently available do not clearly distinguish
among the subtypes. Therefore, to identify the profile of keratinocyte
mAChR, we used a combination of molecular biologic and immuno-
histochemical approaches. We screened keratinocyte RNA using
primers specific for the nucleotide sequences of m1–m5 subtypes of
human mAChR. Because mAChR genes do not have introns, to
distinguish between amplification of genomic DNA and cDNA, we
pretreated keratinocyte RNA samples with DNase I before RT. No
PCR products were obtained if RT was omitted, thus demonstrating
the absence of contaminating genomic DNA in our cDNA samples.
The PCR products corresponding to subtypes m1, m3, m4, and m5,
but not to m2, were obtained. We have shown previously that
fibroblasts express m2 mRNA.2 Therefore, because no m2 mRNA
was detected in our PCR experiments, we believe that the keratinocyte
cultures used as a source of RNA were free of fibroblast contamination.
To visualize keratinocytes expressing each mAChR in epidermis,
we raised polyclonal antibodies against peptide sequences from the
nonhomologous regions of the carboxyl terminus of m1, m3, m4, and
m5. The specificity of the antibodies for the sequences used for
immunization was demonstrated by ELISA with the synthetic peptides.
The finding that antibody can selectively label a specific mAChR
subtype that is expressed in epidermal keratinocytes was verified by
western blotting of SDS-PAGE-resolved cellular proteins. The m1 was
visualized at µ60 kDa, m4 at 65 kDa region, and m5 at 95 kDa,
which corresponds to the molecular weights of these subtypes found
in other tissues (McLeskey and Wojcik, 1990). The immunoblotting
results obtained in this study concur also with those obtained by us
previously, using the M35 monoclonal antibody (Grando et al, 1995b),
which may react with all mAChR subtypes (Carsi-Gabrenas et al,
1997). We reported that amongst the SDS-PAGE-resolved membrane
proteins solubilized from keratinocytes cultured at low, 0.09 mM
Ca11, the M35 antibody labels three protein bands: a duplet at the
60–65 kDa region and single band at µ95 kDa. Those bands apparently
represented m1, m4, and m5. Although the apparent Mr of m3 in
keratinocytes is about 65 kDa, which is smaller than that of m3
expressed in the cerebellar granule cells (McLeskey and Wojcik, 1990),
the m3 band might not be detected at that time because, as demonstrated
in this study, keratinocytes start to express detectable amounts of m3
only after exposure to an elevated extracellular Ca11. The absence
(or underexpression) of m3 in keratinocytes rapidly growing in culture
is consistent with the observation that m3 is coupled to inhibition of
2Buchli R, Ndoye A, Webber R, Grando SA: Identification of m2, m4 and
m5 subtypes of muscarinic receptors in human skin fibroblasts. J Invest Dermatol
110:607, 1998 (abstr.)
cell proliferation in other cell types (Williams and Lennon, 1991). If
m3 had the same biologic function in keratinocytes, then localization
of the m3 immunoreactivity to the epidermal basal layer would indicate
that constant activation of this receptor by endogenous ACh is required
to control proliferation of basal cells in epidermis, stimulated via other
mechanisms, and that interfering with this inhibitory pathway may
lead to a hyperproliferative state.
Early studies employing the M35 antibody also demonstrated that
an intercellular, pemphigus-like staining pattern of epidermal keratino-
cytes for mAChR could be explained by an accumulation of receptor
molecules at the cell membrane areas associated with desmosomes
(Grando et al, 1995b). An important role for mAChR in regulating
cell adhesion and motility has been demonstrated in a series of in vitro
experiments (Grando and Dahl, 1993; Grando et al, 1993a). In this
study, antibodies to m1, m4, and m5, each produced a distinct
intercellular type of staining consistent with an accumulation of these
receptor subtypes at the sites of cell-to-cell attachment. Therefore, it
is tempting to speculate that these mAChR subtypes are intimately
involved with control of cell adhesion and motility.
The appreciable difference in the relative amounts of m1 expressed
by granular cells as compared with basal and prickle cells suggests a
putative relationship for this mAChR subtype with the process of
terminal differentiation that is characteristic of these cells.
Although conspicuous variations in the distributions of mAChR
subtypes in epidermis suggest a unique role for each receptor in leading
keratinocytes through each stage of their development in epidermis,
further studies are needed to define specific biologic functions of each
mAChR subtype. The heterogeneity of the keratinocyte muscarinic
receptor family demonstrated in this study, taken together with the
pleotropic effects of ACh and muscarinic drugs on the cellular functions
of human keratinocytes (reviewed by Grando, 1997), suggest that the
muscarinic pathways play an important role in mediating endogenous
control of epidermal homeostasis by autocrine/paracrine ACh. Vari-
ations in keratinocyte mAChR subtype throughout the development
of immature basal cells into terminally differentiated granular cells are
apparently genetically predetermined. An array of endogenous factors
have been shown to alter the mAChR profile. In addition to steroid
hormones and retinoids (Baumgartner et al, 1993), these include certain
mediators of inflammation (Haddad et al, 1996a) and growth factors
(Haddad et al, 1996b).
The expression of certain mAChR subtype(s) can herald malignant
transformation, because the cholinergic receptor phenotype of malig-
nant melanoma cells is different from that of normal melanocytes
(Grando et al, 1995b; Kohn et al, 1996; Lammerding-Koeppel et al,
1997). The mAChR subtypes may also be selectively targeted in
immune-mediated skin diseases. For instance, patients with Sjogren’s
syndrome develop IgG antibodies that can modify biologic effects
mediated by m3 activation (Bacman et al, 1996). Patients with
pemphigus vulgaris or foliaceus both develop antibodies capable of
precipitating a putative keratinocyte cholinergic receptor labeled with
the muscarinic radioligand propylbenzylilcholine mustard,3 and mus-
carinic agonists can block and reverse pemphigus IgG-induced acantho-
lysis in keratinocyte cultures (Grando and Dahl, 1993). It is also worth
noting that cholinergic stimulation is deficient in both lesional and
nonlesional skin in vitiligo (Elwary et al, 1997), which is associated
with abnormal calcium uptake by both keratinocytes and melanocytes
obtained from vitiliginous epidermis (Schallreuter and Pittelkow, 1988;
Schallreuter-Wood et al, 1996).
Each of the five molecular subtypes of mAChR is preferentially
coupled to a distinct signal transduction pathway. The two intracellular
enzymes that are involved in signaling from mAChR subtypes are
phospholipase C and adenylyl cyclase. It is well established from studies
with transfected cell lines that the expression of the odd-numbered
subtypes couple to pertussis toxin-insensitive G proteins and thereby
stimulate phospholipase C. This causes the release of both phosphatidyl-
inositol, which releases Ca11 from intracellular stores, and diaglycerol,
3Grando SA, Lee TX, Dahl MV: Antibodies to keratinocyte cholinergic
receptor in pemphigus. J Invest Dermatol 108:560, 1997 (abstr.)
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which activates protein kinases. These mAChR also stimulate arachi-
donic acid release, increase cyclic AMP and cyclic GMP levels, and
open Ca11-dependent K1 channels. In contrast, even-numbered
subtypes couple to pertussis toxin-sensitive G proteins and thereby
inhibit (previously stimulated) adenylyl cyclase, weakly stimulate
phospholipase C, open inwardly rectifying K1 channels, inhibit calcium
currents, and augment arachidonic acid release (reviewed by Hosey,
1992; Jones, 1993). It is possible, however, that a single subtype can
couple to either phospholipase C or adenylyl cyclase (Caulfield, 1993).
The mAChR subtypes are distributed heterogeneously throughout
the central nervous system and in the periphery. Cumulative data
obtained from molecular biologic and immunohistochemical studies
demonstrate that m1 is expressed in significant amounts in cerebral
cortex, hippocampus, thalamus, caudate-putamen, and amygdala. The
m2 subtype is found in basal forebrain, caudate-putamen, hippocampus,
hypothalamus, amygdala, and pontine nuclei. The m3 mAChR is
abundant in cerebral cortex, olfactory tubercle, hippocampus, thalamus,
pons, and cerebellum. The m4 subtype is also seen in cerebral cortex,
olfactory tubercle, hippocampus, thalamus, and caudate-putamen. The
m5 is localized to hippocampus, thalamus, striatum, lateral habenula,
medial mammillary nucleus, and cerebellum (reviewed by Caulfield,
1993).
In the periphery, m1 is expressed in sympathetic ganglia and
submaxillary gland (Dorje et al, 1991), in biliary (Elsing et al, 1997)
and prostate epithelia (Ruggieri et al, 1995), in zymogen cells, and, to
a lesser extent, in the surface mucosal and the muscle stomach layers
(Helander et al, 1996). The m2 subtype is found in sympathetic ganglia,
ileum, uterus, heart (Dorje et al, 1991; Hoover et al, 1994), corpus
cavernosum (Toselli et al, 1994), and detrusor and ciliary muscles
(Zhang et al, 1995; Yamaguchi et al, 1996). The m3 mAChR has been
localized to peripheral auditory system (Safieddine et al, 1996), fundic
mucosa, and smooth muscle cells of the gastric tunica muscularis
(Hunyady et al, 1996), enterocytes on rat jejunal villi (Przyborski and
Levin, 1993), submaxillary gland (Dorje et al, 1991), striated and
interlobular salivary gland duct cells (Shida et al, 1993), corneal and
anterior lens epithelia (Gupta et al, 1994), as well as tracheal smooth
muscle, epithelium, and blood vessels, and, to a lesser extent, bronchiolar
smooth muscle (Mak et al, 1993). The m4 is present in bronchiolar
smooth muscle and alveolar walls (Mak et al, 1993), and m5 is
present in arterial endothelium (Phillips et al, 1997). Peripheral blood
mononuclear cells and purified T cells express three mAChR subtypes,
m3, m4, and m5 (Costa et al, 1995; Hellstrom-Lindahl and Nordberg,
1996), as does iris-ciliary body (Gil et al, 1997).
In summary, free ACh (neuroneal or non-neuroneal) is abundantly
present in the surface tissues lining human mucocutaneous membranes
(Grando et al, 1993b; Johansson and Wang, 1993; Klapproth et al,
1997). The diversity of mAChR expressed by keratinocytes allows this
single cytotransmitter to exert different effects at various stages of cell
differentiation. The cutaneous cholinergic network, however, is not
limited to keratinocytes. It is becoming increasingly clear that the cells
inhabiting human skin assemble an intercellular signaling network
wherein ACh acts as a common cytotransmitter mediating intercellular
communications. Normal human skin melanocytes (Iyengar, 1989),
fibroblasts (Vestling et al, 1995), and endothelial cells (Gardner-Medwin
et al, 1997), have all been found to express one or more functional
elements of the cellular cholinergic system. Perhaps, the cholinergic
signals generated by these non-neuroneal cells in response to environ-
mental stimuli are recognized by the PGP 9.5-positive nerves penetrat-
ing epidermis (Grando et al, 1995b), thus providing a functional
neurocutaneous axis of the nervous system.
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